宿:,,

Yifan Yao1,2, Xuemei Wen1,2, Hongjuan Pan1,2

  • 1National Key Laboratory of Lead Druggability Research, Shanghai Institute of Pharmaceutical Industry, Shanghai, China.

Frontiers in microbiology
|September 3, 2025
PubMed
概括

主体细胞蛋白 (HCP) 是生物制药中的杂质,存在安全风险. 这一审查涵盖了医疗人员检测方法,重点是质谱和ELISA,以及未来更好的控制进展.